Loading
Loading
Your feedback directly shapes Sporos.
Sign in to track your feedback history
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.
Introduced
Jan 8, 2025
Last Action
Jan 28, 2026
Session
NY 2025-2026
Sponsors
1 primary · 3 co
REPORTED AND COMMITTED TO FINANCE
REFERRED TO CONSUMER PROTECTION
RETURNED TO SENATE
DIED IN ASSEMBLY
DELIVERED TO ASSEMBLY
REFERRED TO CONSUMER AFFAIRS AND PROTECTION
REPASSED SENATE
VOTE RECONSIDERED - RESTORED TO THIRD READING
RECALLED FROM ASSEMBLY
RETURNED TO SENATE
AMENDED ON THIRD READING 488A
PASSED SENATE
REFERRED TO CONSUMER AFFAIRS AND PROTECTION
DELIVERED TO ASSEMBLY
ADVANCED TO THIRD READING
2ND REPORT CAL.
1ST REPORT CAL.204
REFERRED TO CONSUMER PROTECTION
Get a plain-English explanation of what this bill does, who it affects, and why it matters.
REPORTED AND COMMITTED TO FINANCE
Nathalia Fernandez